Search
DiaMedica Therapeutics Inc
DMACAdd to Watchlist
6.550USD
+0.400+6.50%
Close 06/26, 16:00（ET）Quotes delayed by 15 min
352.94MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+6.50%
5 Days
+11.97%
1 Month
+3.64%
6 Months
-20.41%
Year to Date
-17.71%
1 Year
+71.92%
Key Figures
6.150Open
6.750High
962.88KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.79%Turnover Ratio
6.150Prev. Close
6.020Low
5.81MTurnover
LossP/E Static
7.47P/B
0.00%Div Yield TTM
-76.38%ROA
10.41952wk High
5.17Volume Ratio
-24.44MNet Profit
53.88MShares
-0.7042EPS TTM
1.15Beta
-86.47%ROE
3.19052wk Low
11.87%Amplitude
--Gross Margin
352.94MMarket Cap
-0.04Reward/Risk
3.99%Risk Rate
TradingKey Stock Score of DiaMedica Therapeutics Inc
Currency: USD Updated: 2026-06-26Key Insights
DiaMedica Therapeutics Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 120 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.50.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
DiaMedica Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
DiaMedica Therapeutics Inc Highlights
StrengthsRisks
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -9.30, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 18.70M shares, increasing 3.81% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 2.24M shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
15.500
Target Price
+152.03%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
DiaMedica Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
DiaMedica Therapeutics Inc Info
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
Ticker SymbolDMAC
CompanyDiaMedica Therapeutics Inc
CEOPauls (Rick)
Websitehttps://www.diamedica.com/
Related Instruments
+7.01%
+3.85%
+1.36%
+3.63%
+2.35%
+0.12%
+1.56%
+0.78%
+3.26%
+2.60%
+2.32%
+3.81%
+1.16%
+2.75%
-0.01%
0.00%
+2.06%
+1.31%
-0.17%
+1.76%Popular Instruments
51752.200
-272.500 (-0.52%)
28987.500
-467.500 (-1.59%)
7332.000
-34.800 (-0.47%)
15282.000
-469.000 (-2.98%)
69508.000
-1624.000 (-2.28%)
6207.100
-58.700 (-0.94%)
70.148
-1.196 (-1.68%)
283.780
+8.630 (+3.14%)
192.530
-3.210 (-1.64%)
4087.760
+61.610 (+1.53%)
FAQs
What is the current price of DiaMedica Therapeutics Inc (DMAC)?
The current price of DiaMedica Therapeutics Inc (DMAC) is 6.55.
What is the symbol of DiaMedica Therapeutics Inc?
The ticker symbol of DiaMedica Therapeutics Inc is DMAC.
What is the 52-week high of DiaMedica Therapeutics Inc?
The 52-week high of DiaMedica Therapeutics Inc is 10.42.
What is the 52-week low of DiaMedica Therapeutics Inc?
The 52-week low of DiaMedica Therapeutics Inc is 3.19.
What is the market capitalization of DiaMedica Therapeutics Inc?
The market capitalization of DiaMedica Therapeutics Inc is 352.94M.
Is DiaMedica Therapeutics Inc (DMAC) currently rated as Buy, Hold, or Sell?
According to analysts, DiaMedica Therapeutics Inc (DMAC) has an overall rating of Buy, with a price target of 15.50.
What is the Earnings Per Share (EPS TTM) of DiaMedica Therapeutics Inc (DMAC)?
The Earnings Per Share (EPS TTM) of DiaMedica Therapeutics Inc (DMAC) is -0.70.
